PharmAla Collaborates with University to Advance MDMA Research
TORONTO, Oct. 08, 2024 – PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF) has officially announced its role as a supplier of MDMA for an upcoming clinical trial at the University of Texas, San Antonio. With this partnership, PharmAla aims to deliver a novel dosage form of LaNeo™ MDMA, which will be pivotal in investigator-initiated human trials.
Innovative Dosage Forms Supporting Clinical Trials
“PharmAla is prepared to assist researchers with not only our existing active pharmaceutical ingredients (API) and 40mg capsules but also in creating new dosage forms of LaNeo™ MDMA,” expressed Nicholas Kadysh, CEO at PharmAla Biotech. This initiative reflects the company’s commitment to exploring varied approaches to drug delivery, recognizing the need for diverse dosing strategies for various therapeutic models.
Enhancing Patient Care Through Research
The decision to explore innovative dosage forms underscores PharmAla’s dedication to improving therapeutic outcomes using MDMA in assisted therapies. The existing 40mg dosage structure has been effective in both Canada and Australia; however, the company believes that broadening dosage options will pave the way for greater adaptability in treatment plans for patients.
Recognizing Intellectual Property Advancements
In tandem with research initiatives, PharmAla is proud to announce the recent publication of a key patent application linked to its Intellectual Property (IP) strategy by the US Patent and Trademark Office (USPTO). This application pertains to PharmAla’s APA-01 novel molecular entity, which holds promise for various medicinal applications. The significant technological advancements stem from the original APA-01 patent that was granted earlier this year.
Gratitude for Ongoing Support
Dr. Harpreet Kaur, VP of Research at PharmAla Biotech, expressed appreciation for the support received from partners like IPON. Their assistance, particularly through non-dilutive grants, has been crucial in sustaining PharmAla’s endeavors to file global patents. This collaborative spirit drives the company’s mission of realizing valuable IP opportunities within Canada.
Who is PharmAla Biotech?
PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) stands at the forefront of biotechnology, with a core focus on the development and manufacture of MDXX class molecules, including MDMA. Established with the vision of addressing the pressing need for clinical-grade MDMA, PharmAla works to facilitate clinical trials while also exploring commercial viability in chosen markets. The company has made strides in its research and development endeavors, leading proof-of-concept studies into several families of intellectual property, including its promising candidate, ALA-002.
Commitment to Regulatory Excellence
Recognizing the significance of robust relationships with regulatory bodies, PharmAla is dedicated to redefining success in the psychedelics sector. The company embraces a regulatory-first approach, believing that collaboration with legislators is essential to achieve sustainable progress within this emerging industry.
For additional inquiries, please contact:
Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website: www.PharmAla.ca
Frequently Asked Questions
What is PharmAla Biotech Holdings Inc.?
PharmAla is a biotechnology company specializing in the research, development, and manufacturing of MDMA and other novel derivatives.
What is LaNeo™ MDMA?
LaNeo™ MDMA is a proprietary formulation of MDMA developed by PharmAla, designed for clinical and therapeutic use.
What is the significance of the University of Texas collaboration?
This collaboration aims to support innovative clinical trials that explore new dosage forms of MDMA for therapeutic applications.
How does PharmAla ensure regulatory compliance?
PharmAla maintains a regulatory-first approach, emphasizing strong relationships with regulators to ensure compliance and success in the psychedelics sector.
What are PharmAla's future goals?
PharmAla aims to expand its research initiatives and enhance its intellectual property portfolio while continuing to supply clinical-grade MDMA and novel drugs.
